Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Restem LLC has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. Each of these actions is assigned to a different person, resulting in 3 distinct examiners for the portfolio. Furthermore, these cases are located in the distinct art units, showing a complete lack of overlap in the current examination assignments. This distribution means that every pending matter is being evaluated independently by a different examiner in a different technical group.
The busiest examiner for the company is SCHUBERG, LAURA J, who is responsible for 1 pending office action. Since there are the pending office actions and the distinct examiners, no single examiner has more than 1 case. This requires a prosecution strategy that addresses the specific nuances of the distinct art units, even with the relatively small number of total pending actions. The distinct examiners will each bring a unique perspective to the pending office actions, requiring the applicant to manage separate prosecution tracks simultaneously. Practitioners should be prepared for diverse requirements across the art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHUBERG, LAURA J | 1 | 23.6% | +37.0% |
| BELYAVSKYI, MICHAIL A | 1 | 64.2% | +27.6% |
| CLARKE, TRENT R | 1 | 42.0% | +24.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19264712 | UMBILICAL LINING-DERIVED STEM CELLS FOR TREATING IDIOPATHIC INFLAMMATORY MYOPATHY | SCHUBERG, LAURA J | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19264712 | UMBILICAL LINING-DERIVED STEM CELLS FOR TREATING IDIOPATHIC INFLAMMATORY MYOPATHY | SCHUBERG, LAURA J | 34d |
| 17874767 | METHODS AND COMPOSITIONS OF NATURAL KILLER CELL ADOPTIVE TRANSFER THERAPY | BELYAVSKYI, MICHAIL A | — |
| 17205910 | COMPOSITIONS CONTAINING UMBILICAL CORD LINING STEM CELLS CONDITIONED MEDIUM | CLARKE, TRENT R | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 1644 | 1 |
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19264712 | UMBILICAL LINING-DERIVED STEM CELLS FOR TREATING IDIOPATHIC INFLAMMATORY MYOPATHY | SCHUBERG, LAURA J | 1631 | §103§112 | Final Rejection | 34d | Pending | Jul 09, 2025 |
| 17874767 | METHODS AND COMPOSITIONS OF NATURAL KILLER CELL ADOPTIVE TRANSFER THERAPY | BELYAVSKYI, MICHAIL A | 1644 | §102DP | Non-Final OA | — | Pending | Jul 27, 2022 |
| 17205910 | COMPOSITIONS CONTAINING UMBILICAL CORD LINING STEM CELLS CONDITIONED MEDIUM | CLARKE, TRENT R | 1651 | §103 | Final Rejection | — | Pending | Mar 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial